Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
akcea therapeutics
alnylam pharmaceuticals
3
×
boston
boston blog main
3
×
boston top stories
fda
hereditary transthyretin amyloidosis
inotersen
life sciences
national blog main
national top stories
new york blog main
3
×
new york top stories
patisiran
san diego blog main
san diego top stories
tafamidis
3
×
clinical trials
drugs
onpattro
pfizer
rna interference
san francisco blog main
san francisco top stories
vyndaqel
andrew fire
barry greene
biotech
boston university
craig mello
dan ollendorf
european medicines agency
harvard pilgrim health care
institute for clinical and economic review
john berk
john maraganore
mary o'donnell
nobel prize
regeneron pharmaceuticals
the amyloidosis foundation
What
alnylam
fda
medicine
drug
rna
rnai
uses
afternoon
ago
alnylam’s
approve
approved
approves
awaits
biological
cells
crossed
decades
decision
discovered
ema
employ
europe
fingers
follows
friday
gene
gets
harmful
historic
history
hits
interference
landmark
make
making
method
mute
ok
onpattro
Language
Current search:
tafamidis
×
photo
×
" new york blog main "
×
" alnylam pharmaceuticals "
×
" boston blog main "
×
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision